Bristol-Myers immunotherapy combination extends survival in melanoma – Reuters
The Cerbat Gem |
Bristol-Myers immunotherapy combination extends survival in melanoma
Reuters Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years, according … Bristol-Myers Squibb Enters Collaboration To Leverage Foundation Medicine's Molecular Information Platform BMS to Use Foundation Medicine Platform in Immuno-Oncology Partnership Five things for pharma marketers to know: Monday, April 3, 2017 |
